Action MYNZ MAINZ BIOMED N.V.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Mainz Biomed N.V.

Actions

MYNZ

NL0015000LC2

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 16/07/2024 		Varia. 5j. Varia. 1 janv.
0,4278 USD -0,97% Graphique intraday de Mainz Biomed N.V. -10,89% -63,12%
10/07 Les principales baisses du prémarché MT
09/07 Les plus fortes hausses du prémarché MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test  
EQ
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
GL
Mainz Biomed Provides Half Year 2024 Corporate Update
EQ
Mainz Biomed Provides Half Year 2024 Corporate Update
GL
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
EQ
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
GL
Mainz Biomed Reports Results of 2024 Annual General Meeting
GL
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
EQ
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
GL
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
GL
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
EQ
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
GL
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next-Gen CRC Test
EQ
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
GL
Mainz Biomed N : Announcement of Annual General Meeting of - Form 6-K
PU
Mainz Biomed Reports Full Year 2023 Financial Results
EQ
Mainz Biomed Reports Full Year 2023 Financial Results
GL
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
EQ
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
GL
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action MYNZ
  4. Actualités Mainz Biomed N.V.
  5. Communiqués